Related Experiment Video
Updated: Jun 25, 2025
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care
Nicole Baranda Balmaceda1, Angelica Petrillo2, Mridula Krishnan3
1Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Abstract:
Gastroesophageal cancers (GECs) represent a significant clinical challenge. For early resectable GEC, the integration of immune checkpoint inhibitors into the perioperative chemotherapy and chemoradiation treatment paradigms are being explored and showing promising results. Frontline management of metastatic GEC is exploring the role of targeted therapies beyond PD-1 inhibitors, including anti-human epidermal growth factor receptor 2 agents, Claudin 18.2 inhibitors, and FGFR2 inhibitors, which have shown considerable efficacy in recent trials. Looking ahead, ongoing trials and emerging technologies such as bispecific antibodies, antibody-drug conjugates, and adoptive cell therapies like chimeric antigen receptor T cells are expected to define the future of GEC management. These advancements signify a paradigm shift toward personalized and immunotherapy-based approaches, offering the potential for improved outcomes and reduced toxicity for patients with GEC.
Insights
Advancements in gastroesophageal cancer (GEC) treatment include immunotherapy and targeted therapies for early and metastatic stages. Future strategies focus on personalized medicine and novel agents like bispecific antibodies and CAR T-cells for better patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Gastrointestinal Cancers
Background:
- Gastroesophageal cancers (GECs) pose a significant clinical challenge.
- Current treatment paradigms are evolving rapidly with new therapeutic strategies.
Purpose of the Study:
- To review the current and emerging treatment landscape for gastroesophageal cancers.
- To highlight the role of immunotherapy and targeted therapies in GEC management.
Main Methods:
- Review of recent clinical trials and emerging technologies in GEC treatment.
- Focus on perioperative strategies, targeted therapies, and novel immunotherapeutic approaches.
Main Results:
- Immune checkpoint inhibitors show promise in perioperative settings for resectable GEC.
- Targeted therapies including anti-HER2, Claudin 18.2, and FGFR2 inhibitors demonstrate efficacy in metastatic GEC.
- Emerging technologies like bispecific antibodies, ADCs, and CAR T-cells are under investigation.
Conclusions:
- The management of GEC is shifting towards personalized, immunotherapy-based approaches.
- These advancements offer potential for improved patient outcomes and reduced treatment toxicity.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...